San Francisco – Aug. 19, 2021 – Real Chemistry’s IPM.ai, the leader in uncovering undiagnosed and misdiagnosed patients via machine learning, and Datavant, the leader in helping healthcare and...

Allison Rhee of MM&M reports on IPM.ai's answer to patient finding for rare and specialty diseases through advanced AI/ML. Read the full text below:

The rare disease patient journey can be arduous. Many patients experience multiple misdiagnoses or go undiagnosed before finally figuring out their true health issue and receiving treatment. For...

August 19, 2021

Real Chemistry's IPM.ai Expands Partnership with Datavant to Connect...

0

San Francisco – Aug. 19, 2021 – Real Chemistry’s IPM.ai, the leader in uncovering undiagnosed and misdiagnosed patients via machine learning, and Datavant, the leader in helping healthcare and...

July 29, 2021

Real Chemistry’s IPM.ai Accelerates the Clinical Investigation and...

0

Targeted Approach Optimizes Clinical Study Recruitment of Medically-Eligible Patients Affected by Rare Diseases